Details:

Alternative Title:
Nanoscale
Personal Author:
Lashof-Sullivan, Margaret ; Shoffstall, Andrew ; Lavik, Erin
Lashof-Sullivan, Margaret ; Shoffstall, Andrew ; Lavik, Erin Less -
Description:
Excessive bleeding and the resulting complications are a leading killer of young people globally. There are many successful methods to halt bleeding in the extremities, including compression, tourniquets, and dressings. However, current treatments for internal hemorrhage (including from head or truncal injuries), termed non-compressible bleeding, are inadequate. For these non-compressible injuries, blood transfusions are the current treatment standard. However, they must be refrigerated, may potentially transfer disease, and are of limited supply. In addition, time is of the essence for halting hemorrhage, since more than a third of civilian deaths due to hemorrhage from trauma occur before the patient even reaches the hospital. As a result, particles that can cross-link activated platelets through the glycoprotein IIb/IIIa receptor expressed on activated platelets are being investigated as an alternative treatment for non-compressible bleeding. Ideally, these particles would interact specifically with platelets to stabilize the platelet plug. Initial designs used biologically derived microparticles with red blood cell fragment or albumin cores decorated with RGD or fibrinogen, which bind to GPIIb/IIIa. More recently there has been research into the use of fully synthetic nanoparticles with liposomal or polymer cores that crosslink platelets through a targeting peptide bound to the surface. Some of the challenges for the development of these particles include appropriate sizing to prevent blocking the capillaries of the lungs, immune system evasion to prevent strong reactions and increase circulation time, and storage and resuspension so that first responders can easily use the particles. In addition, the effectiveness of the variety of animal bleeding models in predicting outcomes must be examined before test results can be fully understood. Progress has been made in the development of particles to combat hemorrhage, but issues of immune sensitivity and storage must be resolved before these types of particles can be translated for human use.
Subjects:
[+]
Animals Antifibrinolytic Agents Article Complement System Proteins Erythrocytes Fibrinogen Hemorrhage Humans Injections, Intravenous Lactic Acid Liposomes Nanoparticles Polyglycolic Acid
Source:
Nanoscale. 5(22):10719-10728.
Pubmed ID:
24088870
Pubmed Central ID:
PMC4238379
Document Type:
Journal Article
Funding:
DP2 OD007338/OD/NIH HHS/United States ; DP20D007338/DP/NCCDPHP CDC HHS/United States
DP2 OD007338/OD/NIH HHS/United States ; DP20D007338/DP/NCCDPHP CDC HHS/United States Less -
Collection(s):
CDC Public Access
Main Document Checksum:
[+]
urn:sha256:bd22d9f68fd6333e59dbda161ba935e23454b544ba2e9732ca703f602c17749e
Download URL:
https://stacks.cdc.gov/view/cdc/30180/cdc_30180_DS1.pdf
File Type:

Supporting Files

• 	nihms642274.nxml	bin
  	nihms642274f1.gif	gif
  	nihms642274f1.jpg	jpeg

More +